10.24.12
BMS
3Q Revenues: $3.7 billion (-30%)
3Q Loss: $711 million (earnings were $969 million in 3Q11)
YTD Revenues: $13.4 billion (-15%)
YTD Earnings: $1.0 billion (earnings were $2.9 billion YTD11)
Comments: Revenues were impacted heavily by the U.S. patent expirations for Avapro/Avalide (down 56% to $95 million) and Plavix (down 96% to $64 million). U.S. sales decreased 43% to $2.0 billion in the quarter. International sales decreased 6% to $1.8 billion. Orencia sales were up 32% to $307 million. Yervoy sales were up 48% to $179 million, Sprycel sales grew 25% to $263 million, Onglyza/Kombiglyze sales grew 40% to $178 million, and Baraclude sales grew 11% to $346 million. R&D expenses were $951 million in the quarter, down 2%. The company took a $1.8 billion R&D writedown related to its $2.5 billion acquisition of Inhibitex, after a hepatitis C compound was discontinued in Phase III.
3Q Revenues: $3.7 billion (-30%)
3Q Loss: $711 million (earnings were $969 million in 3Q11)
YTD Revenues: $13.4 billion (-15%)
YTD Earnings: $1.0 billion (earnings were $2.9 billion YTD11)
Comments: Revenues were impacted heavily by the U.S. patent expirations for Avapro/Avalide (down 56% to $95 million) and Plavix (down 96% to $64 million). U.S. sales decreased 43% to $2.0 billion in the quarter. International sales decreased 6% to $1.8 billion. Orencia sales were up 32% to $307 million. Yervoy sales were up 48% to $179 million, Sprycel sales grew 25% to $263 million, Onglyza/Kombiglyze sales grew 40% to $178 million, and Baraclude sales grew 11% to $346 million. R&D expenses were $951 million in the quarter, down 2%. The company took a $1.8 billion R&D writedown related to its $2.5 billion acquisition of Inhibitex, after a hepatitis C compound was discontinued in Phase III.